Novartis AG
cosentyx
hidradenitis suppurativa (HS) in pediatric patients
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on cosentyx for hidradenitis suppurativa (HS) in pediatric patients is expected Date TBD.
Primary source
· SEC 6-K
verified 14h ago
“Cosentyx (secukinumab) FDA approved Cosentyx for the treatment of moderate to severe hidradenitis suppurativa (HS) in pediatric patients aged 12 years and older, making it the only IL-17A inhibitor approved for this population.”